Praveen Tipirneni is the CEO of Morphic Therapeutic, a biotech company pioneering the development of a new generation of oral integrin drugs. With a background in corporate development and global strategy, he has been instrumental in steering the company towards significant advancements in the biotech field. His leadership continues to drive Morphic Therapeutic's mission to innovate and transform integrin-targeted therapies.
Who is the CEO of Morphic Therapeutic?
Before taking the helm at Morphic Therapeutic, Praveen Tipirneni built a robust career in the biotech and pharmaceutical industries. He earned his MD from McGill University in 2005 and later held the position of Senior Vice President of Corporate Development. His journey is marked by significant contributions to the field, including published works in major outlets like HuffPost and Forbes.
As the CEO of Morphic Therapeutic, he leverages his extensive background to drive the company's mission of developing innovative oral integrin drugs.
Work History
Praveen Tipirneni's work history includes a series of significant roles in the biotech and pharmaceutical industries. Here is a detailed list of his previous positions:
- Morphic Therapeutic - CEO (2015 to Present)
- Cubist Pharmaceuticals - Senior Vice President, Corporate Development and Global Strategy (2002 to 2015)
- Deltagen - Corporate Development (2001 to 2002)
Education History
Praveen Tipirneni's educational journey is marked by a series of prestigious institutions and diverse fields of study. He began his academic career at the Massachusetts Institute of Technology, where he earned a Bachelor of Science in Mechanical Engineering from 1986 to 1990. Following this, he pursued a Doctor of Medicine at McGill University, completing his degree between 1991 and 1995. To further enhance his expertise, Tipirneni attended The Wharton School, obtaining an MBA with a focus on Healthcare Finance from 1998 to 2001. This robust educational foundation has equipped him with a unique blend of technical, medical, and financial knowledge, which he leverages in his leadership role at Morphic Therapeutic.
When did Praveen Tipirneni join Morphic Therapeutic?
Praveen Tipirneni joined Morphic Therapeutic as CEO on July 1, 2015. Since then, he has been leading the company, driving its mission to develop innovative oral integrin drugs. With over eight years at the helm, Tipirneni has played a crucial role in steering the company towards significant advancements in the biotech field. His extensive background in corporate development and global strategy has been instrumental in Morphic Therapeutic's growth and success.